.Attribute Medicine, Released online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- medicine conjugate (ADC) tisotumab vedotin caused strengthened progression-free as well as overall survival, triggering FDA commendation and also a brand-new treatment possibility for clients.